Cargando…
Reslizumab as add-on therapy in patients with refractory asthma
Autores principales: | Virchow, J Christian, McDonald, Mirna, Garin, Margaret, Korn, Stephanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254105/ https://www.ncbi.nlm.nih.gov/pubmed/32273395 http://dx.doi.org/10.1136/bmjresp-2019-000494 |
Ejemplares similares
-
Adverse effects of salmeterol in asthma: a neuronal perspective
por: Lommatzsch, M, et al.
Publicado: (2009) -
In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV(1) reversibility
por: Virchow, J. Christian, et al.
Publicado: (2020) -
Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
por: Heaney, Liam G, et al.
Publicado: (2010) -
Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021) -
Maternal history of miscarriages and measures of fertility in relation to childhood asthma
por: Magnus, Maria Christine, et al.
Publicado: (2019)